MedTrace Logo

Glufast On Insulin Glargine Trial in Type 2 DM

NCT00663884 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2012-03-30

No results posted yet for this study

Summary

We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Mitiglinide

mitiglinide 10mg three times a day before a meal

DRUG

Voglibose

voglibose 0.2mg three times a day before a meal

Sponsors & Collaborators

Principal Investigators

  • Kun-ho Yoon · The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-07-31
Completion
2009-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663884 on ClinicalTrials.gov